Evaluation of oropharyngeal infections in febrile neutropenic patients: a study of 335 episodes

Amac Notropenik hastalarda mukozit orofarenks basta olmak uzere tum gastrointestinal sistemde olusabilmektedir.  Mukoza butunlugunun bozulmasi lokal invazyona zemin hazirlar ve onemli bir enfeksiyon odagi haline gelmesine  neden olur. Bu calismada febril notropenik hastalarda gelisen orofarengeal enfeksiyonlarin degerlendirilmesi ve oral  kavite muayenesinin onemine dikkati cekmek amaclanmistir. Yontem Tersiyer bir hastanede uc yil boyunca tani alan hematolojik maligniteli febril notropenik hastalarin demografik  verileri, atak sayisi, malignitelerin dagilimi ve gelisen orofarengeal enfeksiyonlar degerlendirildi. Bulgular Toplam 335 atak geciren 170 hasta calismaya dahil edildi. Mikrobiyolojik olarak dokumante edilen enfeksiyonlarda  en sik bakteremi (n=92, %27.5) vardi. Ikinci en sik enfeksiyon orofarengeal enfeksiyonlardi (n=69, %20.1). Orofarengeal enfeksiyonlardan en sik izole edilen mikroorganizma funguslardi (n=34, %49.3). Sonuc Febril notropenik hastalarin orofarengeal enfeksiyonlari lokalize ve sistemik enfeksiyona ilerleyen klinik tablolara neden olabilir. Hastalarin oral kavitesinin gunluk muayenesi, bakimi ozenli bir sekilde yapilmalidir. Orofarengeal floralari yakin takip edilmeli ve olasi bir enfeksiyon tablosunun oldugu durumlarda buradaki floranin da kaynak olabilecegi mutlaka goz onunde bulundurulmalidir.

[1]  R. Bonomo,et al.  Antibiotic-resistant gram-negative bacterial infections in patients with cancer. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  M. Netea,et al.  Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis , 2014, British journal of haematology.

[3]  H. Wong.  Oral Complications and Management Strategies for Patients Undergoing Cancer Therapy , 2014, TheScientificWorldJournal.

[4]  B. Meddeb,et al.  Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes , 2010, Hematology.

[5]  A. Antoniadou,et al.  Fever of unknown origin in febrile leukopenia. , 2007, Infectious disease clinics of North America.

[6]  J. Szer,et al.  A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  M. Paesmans,et al.  Causes of fever in cancer patients (prospective study over 477 episodes) , 2006, Supportive Care in Cancer.

[8]  H. Sørensen,et al.  Risk of bacteraemia and mortality in patients with haematological malignancies. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[9]  M. Paesmans,et al.  Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  S. Fridkin.  The changing face of fungal infections in health care settings. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  A. Larocca,et al.  A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia , 2005, Supportive Care in Cancer.

[12]  K. Rolston.  Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  P. Johansson,et al.  A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies , 2004, Scandinavian journal of infectious diseases.

[14]  O. Sezer,et al.  Antimicrobial therapy of unexplained fever in neutropenic patients , 2003, Annals of Hematology.

[15]  J. Sobel,et al.  Review articleMucosal candidiasis , 2002 .

[16]  S. Baum.  2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .

[17]  L. Young,et al.  1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  M. Paesmans,et al.  Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer , 1995, Antimicrobial agents and chemotherapy.

[19]  R. Feld,et al.  Ceftazidime Compared with Piperacillin and Tobramycin for the Empiric Treatment of Fever in Neutropenic Patients with Cancer: A Multicenter Randomized Trial , 1994, Annals of Internal Medicine.

[20]  M. Okudaira,et al.  Fungal infections in cancer patients: An international autopsy survey , 1992, European Journal of Clinical Microbiology and Infectious Diseases.

[21]  S. Persson,et al.  Multivariate study of enterobacteria and Pseudomonas in saliva of patients with acute leukemia. , 1991, Oral surgery, oral medicine, and oral pathology.

[22]  G. Bodey.  Infections in cancer patients. , 1975, Cancer treatment reviews.

[23]  P. Lockhart,et al.  Relationship between mucositis and changes in oral microflora during cancer chemotherapy. , 2007, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[24]  V. Diehl,et al.  Once-Daily Oral Levofloxacin Monotherapy versus Piperacillin/Tazobactam Three Times a Day: A Randomized Controlled Multicenter Trial in Patients with Febrile Neutropenia , 2004, International journal of hematology.

[25]  O. Sezer,et al.  Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG—German Cancer Society) , 2003 .

[26]  L. Young,et al.  GUIDELINES FROM THE INFECTIOUS DISEASES SOCIETY OF AMERICA 1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever , 1997 .

[27]  M. Paesmans,et al.  Efficacy and Toxicity of Single Daily Doses of Amikacin and Ceftriaxone versus Multiple Daily Doses of Amikacin and Ceftazidime for Infection in Patients with Cancer and Granulocytopenia , 1993, Annals of Internal Medicine.

[28]  A Veselská,et al.  [Mucosal candidiasis]. , 1991, Casopis lekaru ceskych.

[29]  K. Sepkowitz,et al.  IDSA GUIDELINES Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America , 2022 .